Generate Biomedicines · 公司檔案

公開已核驗進展

當前沒有符合條件的公開已核驗事件。

合作、許可與並購時間線

當前顯示的公開進展中沒有合作、許可或並購節點；這不代表該公司從未發生相關活動。

以上來自最新 0 條已核驗進展。合作事件成立與模型效果、實驗結果或臨床進度分別需要證據。

公開原文線索

• Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer

  Generate Biomedicines official news-release RSS · 行業原文收錄 · 來源發佈：Thu Oct 01 2026 11:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:07:27 GMT+0000 (Coordinated Universal Time)

  Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials First patient treated in new clinical trial underway at Roswel

  原始出處

• Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering

  Generate Biomedicines official news-release RSS · 行業原文收錄 · 來源發佈：Thu Feb 26 2026 23:11:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:07:27 GMT+0000 (Coordinated Universal Time)

  SOMERVILLE, Mass., February 26, 2026 — Generate Biomedicines, Inc. (Nasdaq: GENB) (“Generate”), a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development, t

  原始出處

• Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI

  Generate Biomedicines official news-release RSS · 行業原文收錄 · 來源發佈：Mon Dec 01 2025 10:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:07:27 GMT+0000 (Coordinated Universal Time)

  SOLAIRIA‑1 and SOLAIRIA‑2 will evaluate GB-0895 in approximately 1,600 patients with severe asthma whose disease remains inadequately controlled on current therapies These are the first global Phase 3 studies of a long-a

  原始出處

• Generate:Biomedicines to Present Phase 1 Results for AI-Engineered GB-0895 in Asthma at the European Respiratory Society International Congress

  Generate Biomedicines official news-release RSS · 行業原文收錄 · 來源發佈：Thu Sep 25 2025 11:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:07:27 GMT+0000 (Coordinated Universal Time)

  GB-0895, a next-generation, ultra-high affinity anti-TSLP monoclonal antibody, demonstrated prolonged half-life and sustained pharmacology in asthma patients GB-0895 is optimized for a single subcutaneous injection every

  原始出處

已驗證的官方與訂閱來源

• Generate Biomedicines official news-release RSS · 採集已啓用 · 最近成功 Fri Oct 09 2026 08:07:53 GMT+0000 (Coordinated Universal Time)

來源驗證與持續採集分別顯示；原文收錄不自動成為已核驗事件。